Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | DHODH | Q02127 | 13/20 | 0.42 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12900039 | 0.82 | JAK2 (0.41) | JAK2THRBDHODHTYMPLMNA | |
| SCHEMBL1270655 | 0.78 | CYP1A2 (0.39) | JAK2THRBDHODHLMNAALDH1A1 | |
| SCHEMBL11250095 | 0.77 | JAK2 (0.48) | JAK2THRBDHODH | |
| SCHEMBL11245596 | 0.77 | JAK2 (0.48) | JAK2THRBDHODHLMNAALDH1A1 | |
| SCHEMBL11242987 | 0.77 | JAK2 (0.48) | JAK2THRBDHODHTYMP | |
| Water SCHEMBL11246907 | 0.76 | JAK2 (0.47) | JAK2THRBDHODHTYMP | |
| SCHEMBL9715507 | 0.72 | JAK2 (1.00) | JAK2THRBDHODHTYMPLMNA | |
| SCHEMBL44527 | 0.72 | JAK2 (1.00) | JAK2THRBDHODHTYMPLMNA | |
| SCHEMBL22783664 | 0.72 | JAK2 (0.61) | JAK2THRBDHODHLMNAALDH1A1 | |
| SCHEMBL10629768 | 0.71 | JAK2 (0.96) | JAK2THRBDHODHTYMPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0445239-A4 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | — | 1992-03-25 | — | — | EP | claimed |
| EP-0445239-A1 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1991-09-11 | — | — | EP | claimed |
| WO-1991000081-A2 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1991-01-10 | — | — | WO | claimed |
| EP-1947092-B1 | Method for producing nucleic acid base having perfluoroalkyl group | TOSOH CORP (JP) | 2015-04-15 | — | — | EP | disclosed |
| CN-101304977-B | Nucleic acid base having perfluoroalkyl group and method for producing the same | TOSOH CORP | 2014-08-13 | — | — | CN | disclosed |
| US-7884202-B2 | Nucleobases are perfluoroalkylated in a one step process with a perfluoroalkyl halide in the presence of a sulfoxide, a peroxide and an iron compound; useful as medicinal drugs, intermediates for medicinal drugs and agricultural chemicals | TOSOH CORPORATION (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884202-B2 | Nucleobases are perfluoroalkylated in a one step process with a perfluoroalkyl halide in the presence of a sulfoxide, a peroxide and an iron compound; useful as medicinal drugs, intermediates for medicinal drugs and agricultural chemicals | TOSOH CORPORATION (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884202-B2 | Nucleobases are perfluoroalkylated in a one step process with a perfluoroalkyl halide in the presence of a sulfoxide, a peroxide and an iron compound; useful as medicinal drugs, intermediates for medicinal drugs and agricultural chemicals | TOSOH CORPORATION (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20090124796-A1 | Nucleobase Having Perfluoroalkyl Group and Process for Producing the Same | TOSOH CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-1947092-A1 | NUCLEIC ACID BASE HAVING PERFLUOROALKYL GROUP AND METHOD FOR PRODUCING THE SAME | Tosoh Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| EP-1947092-A1 | NUCLEIC ACID BASE HAVING PERFLUOROALKYL GROUP AND METHOD FOR PRODUCING THE SAME | Tosoh Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-6159953-A | Anti-malarial composition and method of use | CATHOLIC UNIVERSITY OF AMERICA (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0445239-A4 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | — | 1992-03-25 | — | — | EP | disclosed |
| EP-0445239-A1 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1991-09-11 | — | — | EP | disclosed |
| WO-1991000081-A2 | ANTI-MALARIAL COMPOSITION AND METHOD OF USE | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1991-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124796-A1 | Nucleobase Having Perfluoroalkyl Group and Process for Producing the Same | PFAS, FPGS, NUDT1 | JAK2 3794/4885THRB 2374/4885DHODH 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.